Drug Trial Radar · NCT02563327
Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis
Last checked: Nov 20, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,516
Actual
Start
Jan 25, 2016
Primary completion
Aug 30, 2021
Study completion Aug 30, 2021
Sponsor
- Lead sponsor
- Centers for Disease Control and PreventionFederal agency
- Sponsor type
- Federal agency
- Collaborators
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- First posted
- Sep 30, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Tuberculosis Trials Consortium (TBTC) Study 31 is a phase 3 trial evaluating rifapentine-containing regimens for treatment-shortening of drug-susceptible pulmonary tuberculosis. This pharmacokinetic/pharmacodynamic (PK/PD) substudy evaluates rifapentine and moxifloxacin exposure-response relationships for efficacy and safety outcomes. Intensive and sparse PK sampling are performed among participants receiving rifapentine-containing regimens. PK and clinical outcomes data are used to characterize population pharmacokinetics and assess relationships between drug exposure, culture conversion, treatment failure or relapse, and adverse events.
Conditions
- Tuberculosis
Interventions
RifapentineDrug
A rifamycin with activity against Mycobacterium tuberculosis
MoxifloxacinDrug
A fluoroquinolone
RifampinDrug
A rifamycin with activity against Mycobacterium tuberculosis
IsoniazidDrug
An anti-tuberculosis agent
PyrazinamideDrug
An anti-tuberculosis agent
EthambutolDrug
An anti-tuberculosis agent
PyridoxineDietary supplement
An essential vitamin
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rifapentine Area Under the Concentration-Time Curve From 0 to 24 Hours (AUC0-24)Time frame: Plasma concentrations measured at approximately 0.5, 3, 5, 9, 12, and 24 hours after the pharmacokinetic reference dose during Weeks 2-8 after treatment initiation.
- Rifapentine Maximum Plasma Concentration (Cmax)Time frame: Plasma concentrations measured during 0-24 hours following the pharmacokinetic reference dose; PK sampling performed during Weeks 2-8 after treatment initiation.
Locations
3 sites in 3 countries. Site status is shown where the registry gives one.
University of Texas Health Science Center at
San Antonio, Texas
Joint Clinical Research Centre/ Makerere Univ Med Sch
Kampala, Uganda
National TB Program
Hanoi, Vietnam
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.